As promised, Novartis eyes new method for funding ultrapricey next-gen drugs: FT

17th December 2018 Uncategorised 0

Novartis is weighing an insurance method often associated with natural disasters to help win coverage for its pricey next-generation cell and gene therapies. Reinsurance would underwrite a different sort of catastrophe, Novartis CEO Vas Narasimhan told the Financial Times. 

More: As promised, Novartis eyes new method for funding ultrapricey next-gen drugs: FT
Source: fierce